SuperworthKalaris Therapeutics KLRS
- Market cap
- $44.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | −$34.2M | $232.8M+719% | $2M−94% | $3.2M−91% | $36M | $3.9M−98% | $6M+208% | $8.4M+163% | $9.1M−75% | $7.2M+86% | $7.6M+26% | $9M+7% |
| SG&A | $12.8M−1% | $10.5M−13% | $602K−95% | $976K−92% | $1.8M−86% | $3.3M−69% | $4.3M+618% | $3.8M+291% | $3.6M+98% | $3.6M+11% | $4.3M−2% | $3.4M−12% |
| −$47M+9% | −$62.4M+54% | −$2.6M−94% | −$4.2M−91% | −$37.8M−19% | −$7.1M−89% | −$10.4M+304% | −$12.3M+193% | −$12.7M−66% | −$10.8M+51% | −$11.8M+14% | −$12.4M+1% | |
| Interest expense | n/a | n/a | $78K | $499K | $815K | $1.3M | $1.4M+1750% | $0 | $0 | $0 | $0 | $0 |
| Pre-tax income | −$44.3M+5% | −$59.8M+55% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| $0 | −$126K−70% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$44.3M+5% | −$59.7M+57% | −$3.4M−92% | −$5.7M−88% | −$38.1M−14% | −$22M−63% | −$10.2M+199% | −$11.3M+101% | −$11.9M−69% | −$10M−55% | −$10.9M+7% | −$11.5M+2% |
| −$8.97−22% | −$11.96+27% | −$2.60−74% | −$4.26−61% | −$28.16+214% | −$3.64−70% | −$2.52−3% | −$0.61−86% | −$0.64−98% | n/a | −$0.46−82% | −$0.48−21% | |
| 5M+34% | 5M+23% | 1.3M−68% | 1.3M−68% | 1.4M−73% | 5M+1% | 4.1M+209% | 18.7M+1311% | 18.7M+1283% | n/a | 23.7M+485% | 23.8M+27% |
R&D: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY19 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY19: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY19 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x23).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Kalaris Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KLRSKalaris Therapeutics | $44.5M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Kalaris Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .